Fermentalg Launches Capital Increase to Boost Commercial Growth

Fermentalg has initiated a capital increase of approximately €10 million to accelerate its commercial development. The offer targets qualified investors and specific beneficiaries through an accelerated book-building process. Notably, Vatel Capital and Huvepharma have committed approximately €9 million in subscription. The offer closes on May 13, 2026, with shares priced at €0.46, marking a 20% discount.

The fundraising aims to sustain short and medium-term commercial momentum. Recent financial results included a record €3.7 million quarterly turnover. Fermentalg expects sales to rise, driven by new products like the ΩRIGINSTM algae oil and Galdieria BlueTM, amidst rising fish oil prices. Proceeds will fund market expansion, innovation, and working capital.

Huvepharma confirms its strong support by participating in this capital increase. Following their merger in 2023, Huvepharma has heavily invested in Fermentalg, furthering their commitment with a €2 million subscription in this round. The final offering results will be announced post-order book closure, with new shares trading on Euronext Growth Paris by May 15, 2026.